The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia
Open accessAbstract
OBJECTIVES: To evaluate the efficacy and safety of two once-daily doses of tamsulosin, the first selective alpha1A-antagonist studied in clinical trials. METHODS: Patients with benign prostatic hyperplasia (BPH) were randomized to receive either tamsulosin (0.4 and 0.8 mg/day) or placebo (n = 756). Primary efficacy parameters were improvement in the total American Urological Association (AUA) symptom score and peak urinary flow (Qmax). Secondary efficacy parameters were improvement in measurements at individual double-blind visits corresponding to the primary efficacy parameters; percentage of patients with a 3-mL/s increase in Qmax; total AUA irritative, obstructive, and bother scores; individual AUA symptom scores; total, irritative, obstructive, and individual Boyarsky symptom scores; average urinary flow rate and other uroflowmetric parameters; and investigator's global assessment. RESULTS: Statistically significant improvements in all efficacy parameters were observed in tamsulosin-treated compared with placebo-treated patients. Additionally, the 0.4-mg/day dose demonstrated a rapid onset of action (4 to 8 hours) based on Qmax after the first dose of double-blind medication. A review of the safety parameters demonstrated excellent tolerance at 1 week after the initial 0.4-mg/day dose and continued tolerance during the additional 12 weeks of 0.4- and 0.8-mg/day dosing. The incidence of positive orthostatic test results in the tamsulosin groups was comparable to that observed in the placebo group. Adverse events were comparable in the 0.4-mg/day tamsulosin and placebo groups and were somewhat higher in the 0.8-mg/day tamsulosin group. CONCLUSIONS: Tamsulosin was effective, safe, and well tolerated in the target BPH population at both the 0.4- and 0.8-mg/day dose levels, without the blood pressure-lowering effects typical of nonselective alpha-adrenergic antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walsh, M. P. C. (1986) · Cited by 3,471
The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., & Padley, R. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350801 · Cited by 792
Self-citationLepor, H., Auerbach, S., Puras-Baez, A., Narayan, P., Soloway, M., Lowe, F., Moon, T., Leifer, G., & Madsen, P. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36941-0 · Cited by 303
Self-citationLowe, F. C. (1994) · Urology · doi:10.1016/s0090-4295(94)80008-1 · Cited by 61
Cited by
Rosen, R., Altwein, J., Boyle, P., Kirby, R. S., Lukacs, B., Meuleman, E., O’Leary, M. P., Puppo, P., Robertson, C., & Giuliano, F. (2003) · European Urology · doi:10.1016/j.eururo.2003.08.015 · Cited by 1,118
Management of Overactive Bladder
Ouslander, J. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032662 · Cited by 411
Djavan, B., & Marberger, M. (1999) · European Urology · doi:10.1159/000019919 · Cited by 409
Gacci, M., Eardley, I., Giuliano, F., Hatzichristou, D., Kaplan, S. A., Maggi, M., McVary, K. T., Mirone, V., Porst, H., & Roehrborn, C. G. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.037 · Cited by 279
Braun, M. H., Sommer, F., Haupt, G., Mathers, M. J., Reifenrath, B., & Engelmann, U. H. (2003) · European Urology · doi:10.1016/s0302-2838(03)00358-0 · Cited by 255
Metadata
- Authors
- Lepor, H.
- Venue
- Urology
- Publisher
- Elsevier BV
- Published
- 1998-06
- Volume
- 51
- Issue
- 6
- Pages
- 892-900
- ISSN
- 0090-4295 (ISSN-L)
- OpenAlex
- W2135421268
- Cited by
- 367
- References
- 4
- FWCI
- 24.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia. https://app.cochat.ai/papers/10.1016/s0090-4295(98)00126-5
- The paper
- Lepor, H. (1998). Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia. Urology. https://doi.org/10.1016/s0090-4295(98)00126-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.